Database

Startups

Main Industry
Biotechnology
Main Product/Service
RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and
Founded Year
2023
Unified Business No.
94106815
Status
Active
Number of Employees
0
Total Paid-in Capital
18,702,173 (NT$)
Location of Company
Taiwan , Taipei City
Overseas Development
United States of America
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
RephImmune is a preclinical-stage biotech company incubated in Boston and incorporated in Taiwan. We are dedicated to revolutionizing solid tumor cell therapy through our groundbreaking technology, RACE (Reconstitute-Immunity Antigen-Cell Engager): a uniq



More ↓

Similar Companies

ACT GENOMICS CO., LTD.

SOLUTION -
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)